Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.

It was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession sparked by the ongoing global trade war. Most bigwigs came out with important ...

Pacira Biosciences leads in non-opioid pain relief with Exparel & upcoming knee osteoarthritis therapy. Click here to read my ...

Pacira BioSciences (PCRX) stock soars 15% after resolving a patent dispute on non-opioid pain therapy, Exparel with a unit of ...

Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

(RTTNews) - Pacira BioSciences Inc. (PCRX) announced that it has settled its litigations with Fresenius Kabi USA, LLC, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals ...

BioSciences announced that it has settled its litigations with Fresenius Kabi USA, LLC (Fresenius), Jiangsu Hengrui ...

"China's biotechnology sector thrives on a dual engine — Beijing's constellation of famous medical universities training ...

Pharmaceutical stocks fell across Asian markets after U.S. President Trump said he plans to impose a "major" tariff on all pharmaceutical imports.

Pacira BioSciences settles US patent litigations with three companies for Exparel: Brisbane, California Wednesday, April 9, 2025, 15:00 Hrs [IST] Pacira BioSciences, Inc, the indu ...

Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) leaped 15% following the announcement of a settlement in U.S. patent litigation concerning its flagship product, EXPAREL. The agreement effectively ...

HIES and HRC had announced partnering to optimise compressed air system efficiency for HRC’s operations. The reinforced ...